Search

Search Constraints

You searched for: Author/Creator Song, Alexandra

Search Results

1. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Issue 10340 (28th May 2022)

2. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Issue 10340 (28th May 2022)

3. S0648 Clinically Adjusted vs Therapeutic Drug Monitoring Dosing Regimens With Adalimumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the SERENE-CD Maintenance Study. (October 2020)

4. S38 On-Body Injector Administration of Risankizumab for Treatment of Moderate-to-Severe Crohn's Disease: Data From the Fortify Open-Label Longitudinal Real-Life Handling Substudy. (December 2022)

5. S695 Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies. (October 2021)

6. S714 52-Week Risankizumab Subcutaneous Maintenance Dosing Is Efficacious and Well Tolerated in Patients With Moderate to Severe Crohn's Disease Who Had Delayed Response to 12-Weeks IV Risankizumab Induction. (October 2022)

7. S748 Risankizumab Results in Improvements in Disease Activity Scores in Patients With Crohn's Disease: Post-Hoc Analysis of the Phase 3 Induction and Maintenance Studies. (October 2022)

8. S754 Risankizumab as Induction Therapy in Patients with Moderately to Severely Active Crohn's Disease Who Failed 1 vs >1 Prior Biologic Treatment: Results From the MOTIVATE Study. (October 2021)

9. S772 Risankizumab Therapy Induces Improvements in Endoscopic Endpoints in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies. (October 2021)

10. S808 Mechanisms of Non-Response to Adalimumab on Inflammatory Bowel Disease: Peripheral Proteomic and Transcriptomic Profiling from the SERENE-CD and SERENE-UC Studies. (October 2021)